Pharmacoeconomics of darunavir. - Wikidata - awgldk - TriplyDB

Pharmacoeconomics of darunavir.

Pharmacoeconomics of darunavir.

http://www.wikidata.org/entity/Q37847151

about

Pharmacoeconomics of darunavir.

http://www.wikidata.org/entity/Q37847151

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmacoeconomics of darunavir.

@en

Pharmacoeconomics of darunavir.

@nl

type

label

Pharmacoeconomics of darunavir.

@en

Pharmacoeconomics of darunavir.

@nl

prefLabel

Pharmacoeconomics of darunavir.

@en

Pharmacoeconomics of darunavir.

@nl

P1433

Q37847151-ED510F18-CAD8-4725-AEBC-6F6641521CD1

P1476

Q37847151-460F6AA4-23A7-4CEE-8FEA-1E26D03AFBB7

P2093

Q37847151-04B88012-E76A-41D1-BC27-A16E30F32586

Q37847151-43D9DDC2-4EDC-420A-831E-96D5ED46D4F5

Q37847151-882FF072-4549-400D-826D-FC8C463B6CD5

Q37847151-A0EF0345-5AA1-4E4E-8B9C-6EBE337A1392

P2860

Q37847151-1CEAC527-0E3D-4ABD-9D34-ED2F8C9D55DE

Q37847151-247EF9A7-6476-474E-AC44-007067836613

Q37847151-3354345F-0D9C-4635-BC7B-6F32897C25DB

Q37847151-344A276C-B8A4-44C0-857B-277224A4D6A1

Q37847151-4C712452-D7B1-4200-A2C7-897BA46A3E98

Q37847151-6251D72F-4003-4CED-809E-A43CB19BA8A7

Q37847151-62CEB3E5-4B59-4B98-BEB9-D29D0795AACC

Q37847151-697610CF-D12A-46D4-9144-15970FE7B5F9

Q37847151-6C0AB1A0-D80E-4823-B336-E37235A9D06D

Q37847151-7B8D484D-AE92-4AA9-85F2-B12B858E986F

P304

Q37847151-93D7972B-D6AC-49A3-B09B-04C14A3C5BAE

P31

Q37847151-A30A7289-557D-4088-BAA2-F870E6CD2D63

P356

Q37847151-42D4681E-344E-4E97-B5BC-E6D34FDAD11E

P433

Q37847151-CAC792BB-B37E-476A-A3FB-235302A975FC

P478

Q37847151-FB10826B-F53B-4E55-84EE-D029ED9FD3F6

P577

Q37847151-02C7F7B6-0546-4749-AB4A-AC1457F15E69

P698

Q37847151-9D99FE16-102E-471F-BC0A-4349EBDD8C14

P356

P1433

Expert Review of Pharmacoeconomics & Outcomes Research

P1476

Pharmacoeconomics of darunavir.

@en

P2093

Dwight S Fullerton

http://www.w3.org/2001/XMLSchema#string

Erik Smets

http://www.w3.org/2001/XMLSchema#string

Guy De La Rosa

http://www.w3.org/2001/XMLSchema#string

Joseph M Mrus

http://www.w3.org/2001/XMLSchema#string

P2860

The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States

Raltegravir with optimized background therapy for resistant HIV-1 infection

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data.

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

Contemporary costs of HIV healthcare in the HAART era

HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.

Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.

P304

27-39

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERP.10.88

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21351854

http://www.w3.org/2001/XMLSchema#string